Inclusion Criteria

Inclusion criteria:

- Histologically or cytologically proven cholangiocellular carcinoma.

- Non-resectable cholangiocellular carcinoma as judged within an interdisciplinary
tumor-board including senior hepatobiliary surgeons. Non- resectability is based on
insufficient remnant liver volume.

- Patient is not a candidate for liver transplantation

- WHO Performance Score 0 or 1

- No extrahepatic tumor, as evaluated by PET/CT scan of the chest and the
abdomen/pelvis with the exception of potentially resectable small lung nodules or
hilar lymph node involvement.

- The assessment is done within 21 days before registration.

- Adequate liver function or kidney function tests, including any of the following:

- Bilirubin < 2 x ULN

- Aspartate-Aminotransferase (AST) < 5 x ULN

- Alanine-Aminotransferase (ALT) < 5 x ULN

- Alkaline phosphatase < 5 x ULN

- Estimated creatinine clearance > 60 ml/min (using the Cockcroft formula)

- Adequate hematological values:

- Hemoglobin > 80 G/L

- Leucocytes > 3.00 G/L,

- Neutrophils > 1.00 G/Ll

- Platelets > 100 G/L

- Adequate coagulation parameter: Quick > 40%

- Signed written informed consent

- Patient age >/= 18 years

- Presentation of the case at the interdisciplinary tumor-board attended by
hepatobiliary surgeons, oncologists, hepatologists and radiologists

- Women who are not breastfeeding and are using effective contraception if sexually
active, who are not pregnant and agree not to become pregnant during the 12 months
thereafter. A negative pregnancy test before inclusion into the trial is required for
women < 50 years.

- Men who agree not to father a child during participation in the trial or during the
12 months thereafter.

- Patient compliance and geographic proximity allow proper staging and follow- up.

Exclusion criteria:

- Anatomic variant in arteriogram which prevents selective delivery of the chemotherapy
to the liver

- Life expectancy < 3 months

- Severe medical or psychiatric co-morbidity prohibiting the planned treatment or the
giving of informed consent

- Any man or woman of childbearing age in case of inadequate contraception

- Pregnancy or breastfeeding woman

- Known hypersensitivity to trial drugs or hypersensitivity to any other component of
the trial drugs.

- Past or current use of other anti-cancer therapy

- Treatment in clinical trial within 30 days prior to trial entry.

- Oral anticoagulation and/or Quick = 40%

- Active heart disease defined as congestive heart failure > NYHA class 2

- Past or current history (within the last 2 years prior to treatment start) of other
malignancies except basal and squamous cell carcinoma of the skin or in situ
carcinoma of the cervix

- Inability or unwillingness to comply with the study protocol